Skip to main content
SpringerLink
Log in

A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting

  • Original Articles
  • 5HT3-receptor, Antagonist, Chemotherapy, Granisetron, BRL43694A
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

In a phase I study of BRL43694A, a 5HT3-receptor antagonist, a single dose of 40 μg/kg was given to 24 patients. All patients received cytostatic treatment expected to cause nausea and vomiting. During the first 24 h, 12 patients were completely protected from nausea and vomiting, 4 experienced nausea and 8 had moderate vomiting; mild headache occurred in 10 patients. No cardiovascular (including ECG) changes took place. Apart from headache, no neurological side effects occurred.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Addleman M, Erlichman O, Warr D, Fine S, Murray C (1988) Phase I trial of BRL43694, a 5-HT3 antagonist in the prevention of chemotherapy induced nausea and vomiting (Abstract 297). Proc Am Soc Clin Oncol 7: 77

    Google Scholar 

  2. Beecham Pharmaceuticals (March 1988) Clinical Brochure BRL43694A. A novel antiemetic agent

  3. Carmichael J, Cantwell B, Edwards C, Harris AL, Coates P, Thompson S, Rapeport G (1988) Phase I and pharmacokinetic study of BRL43694A selective 5HT3 receptor antagonist: effective control of cisplatin induced emesis (Abstract 1082). Proc Am Soc Clin Oncol 7: 279

    Google Scholar 

  4. Cassidy J, Lewis C, Adams L, Rapeport WG, Zussman BD, Raina V, Soukop M, Kaye SB (1988) Anti-emetic activity and pharmacokinetics of BRL43694A, a selective 5-HT3 antagonist in cancer chemotherapy (Abstract 1418). Proc Am Assoc Clin Res 29: 356

    Google Scholar 

  5. Gumbrell LA, Qualmann C, Perren TJ, Forgeson G, Calvert AH, Thompson S, Rapeport WG (1988) An open pilot study of the 5-HT3 antagonist, BRL43694, an effective antiemetic in refractory highly emetogenic cytotoxic drug induced emesis (Abstract 1149). Proc Am Soc Clin Oncol 7: 296

    Google Scholar 

  6. Joss R, Rohrbach D, Pirovino M, Brunner K, Terrey JP (1988) BRL43694: a novel antiemetic to prevent chemotherapy-induced nausea and vomiting (Abstract 1128). Proc Am Soc Clin Oncol 7: 291

    Google Scholar 

  7. Khojasteh A, Ruble K, Chambers J, Coleman J, Ahmed K (1988) The antiemetic response to GR-C507/75 (GR-38032F) (GR) in patients (Pts) receiving multiple-dose cisplatin (DDP) regimens (Abstract 1159). Proc Am Soc Clin Oncol 7: 298

    Google Scholar 

  8. Kris MG, Gralla RJ, Tyson LB, Clark RA (1988) Phase I and pharmacologic study of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic (Abstract 1099). Proc Am Soc Clin Oncol 7: 283

    Google Scholar 

  9. Leibundgut U, Rabineau A, Obrecht JP (1988) ICS 205-930: a 5HT3 receptor antagonist to prevent cisplatin-induced emesis (Abstract 1100). Proc Ams Soc Clin Oncol 7: 284

    Google Scholar 

  10. Miner WD, Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxy-tryptamine M-receptor antagonism. Br J Pharmacol 88: 497

    Google Scholar 

  11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649

    Google Scholar 

  12. Plezia PM, Davis LE, Alberts DS, Davis A, Garewal HS, Greenberg BR, Smaldone L, Fairchild C (1988) BMY-25801: an effective single agent antiemetic (A) for cisplatin (C)-induced nausea (N) and vomiting (V) (Abstract 1143). Proc Am Soc Clin Oncol 7: 294

    Google Scholar 

  13. Smaldone L, Fairchild C, Rozencweig M, Aapro M, Sartiano G, Plezia P, Alberts D (1988) Dose-range evaluation of BMY-25801, a non dopaminergic antiemetic (Abstract 1086). Proc Am Soc Clin Oncol 7: 280

    Google Scholar 

  14. Stables R, Andrews PLR, Bailey HE, Costall B, Gunning SJ, Hawthorn J, Naylov RJ, Tyes MB (1987) Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev 14: 333

    Google Scholar 

  15. Zulian G, Selby P, Viner C, Grove M, Patel P, Butcher M, McElwain T (1988) GR38032F (GR) — A safe and effective antiemetic in patients receiving high-dose melphalan (M) (Abstract 1123). Proc Am Soc Clin Oncol 7: 289

    Google Scholar 

  16. Plezia PM, Davis LE, Alberts DS, Davis A, Garewal HS, Greenberg BR, Smaldone L, Fairchild C (1988) BMY-25801: an effective single agent antiemetic (A) for cisplatin (C)-induced nausea (N) and vomiting (V) (Abstract 1143). Proc Am Soc Clin Oncol 7: 294

    Google Scholar 

  17. Smaldone L, Fairchild C, Rozencweig M, Aapro M, Sartiano G, Plezia P, Alberts D (1988) Dose-range evaluation of BMY-25801, a non dopaminergic antiemetic (Abstract 1086). Proc Am Soc Clin Oncol 7: 280

    Google Scholar 

  18. Stables R, Andrews PLR, Bailey HE, Costall B, Gunning SJ, Hawthorn J, Naylov RJ, Tyes MB (1987) Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev 14: 333

    Google Scholar 

  19. Zulian G, Selby P, Viner C, Grove M, Patel P, Butcher M, McElwain T (1988) GR38032F (GR) — A safe and effective antiemetic in patients receiving high-dose melphalan (M) (Abstract 1123). Proc Am Soc Clin Oncol 7: 289

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University of Pretoria, Republic of South Africa

    Geoffrey Falkson & Adriaan J. van Zyl

Authors
  1. Geoffrey Falkson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adriaan J. van Zyl
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by a grant from the National Cancer Association of South Africa

Rights and permissions

Reprints and permissions

About this article

Cite this article

Falkson, G., van Zyl, A.J. A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother. Pharmacol. 24, 193–196 (1989). https://doi.org/10.1007/BF00300242

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00300242

Keywords

Search

Navigation